More recently, in January 2025, we achieved a $14 million research milestone from GSK under our 2016 license ... threshold level of incidence. In blue font are the molecules we’ve already ...

The acquisition aligns with GSK's strategy to bolster its oncology portfolio, particularly in precision medicines for cancer. IDRX-42 has received Fast Track designation by the U.S. FDA for the ...

The acquisition aligns with GSK’s strategy to bolster its oncology portfolio, particularly in precision medicines for cancer. IDRX-42 has received Fast Track designation by the U.S. FDA for the ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.